Development of PEGylated solid lipid nanoparticles of pentoxifylline for their beneficial pharmacological potential in pathological cardiac hypertrophy

References

• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 5:505–515.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Singh M. 2005. The possible role of TNF-alpha in physiological and pathophysiological cardiac hypertrophy in rats. Iran J Pharmacol Ther. 4:138–142.
   Google Scholar
• Champion S, Lapidus N, Cherié G, Spagnoli V, Oliary J, Solal AC. 2014. Pentoxifylline in heart failure: a meta‐analysis of clinical trials. Cardiovasc Ther. 32:159–162.
   PubMed Web of Science ®Google Scholar
• Chaudhari KR, Ukawala M, Manjappa AS, Kumar A, Mundada PK, Mishra AK, et al. 2012. Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier. Pharm Res. 29:53–68.
   PubMed Web of Science ®Google Scholar
• Chmielewska A, Konieczna L, Plenis A, Lamparczyk H. 2006. Quantitative determination of pentoxifylline in human plasma. Acta Chromatogr. 16:70–79.
   Web of Science ®Google Scholar
• Kim KP, Cha JD, Jang EH, Klumpp J, Hagens S, Hardt WD, et al. 2008. PEGylation of bacteriophages increases blood circulation time and reduces T‐helper type 1 immune response. Microbial Biotechnol. 1:247–257.
   PubMed Web of Science ®Google Scholar
• Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. 2004. Hypertensive myocardial fibrosis and diastolic dysfunction another model of inflammation? Hypertension. 43:739–745.
   PubMed Web of Science ®Google Scholar
• Li J, Li P, Feng X, Li Z, Hou R, Han C, Zhang Y. 2003. Effects of losartan on pressure overload‐induced cardiac gene expression profiling in rats. Clin Exp Pharmacol Physiol. 30:827–832.
   PubMed Web of Science ®Google Scholar
• Lima V, Vidal FD, Rocha FAC, Brito GAC, Ribeiro RA. 2004. Effects of tumor necrosis factor-α inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats. J Periodontol. 75:162–168.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D. 2010. Heart disease and stroke statistics—update: a report from the American Heart Association. Circulation. 121:e46–e215.
   PubMed Web of Science ®Google Scholar
• Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, Hickerson RP, Leake D, Kaspar RL, et al. 2011. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 5:9977–9983.
   PubMed Web of Science ®Google Scholar
• Mielniczuk LM, Lamas GA, Flaker GC, Mitchell G, Smith SC, Gersh BJ, et al. 2007. Left ventricular end‐diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction. Congest Heart Fail. 13:209–214.
   PubMedGoogle Scholar
• Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G, Karp CL. 1997. Inhibition of human interleukin‐12 production by pentoxifylline. Immunology. 91:197–203.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 50:161–177.
   PubMed Web of Science ®Google Scholar
• Nunes S, Barros A. 2015. The use of coating agents to enhance liposomes blood circulation time. J Mol Pharm Org Process Res. 3:e120.
   Google Scholar
• Parhi R, Suresh P. 2010. Production of solid lipid nanoparticles—drug loading and release mechanism. J Chem Pharm Res. 2:211–227.
   Google Scholar
• Simón-Yarza T, Formiga FR, Tamayo E, Pelacho B, Prosper F, Blanco-Prieto MJ. 2013. PEGylated-PLGA microparticles containing VEGF for long term drug delivery. Int J Pharm. 440:13–18.
   PubMed Web of Science ®Google Scholar
• Singh AP, Singh R, Krishan P. 2015. Ameliorative role of gemfibrozil against partial abdominal aortic constriction-induced cardiac hypertrophy in rats. Cardiol Young. 25:725–730.
   PubMed Web of Science ®Google Scholar
• Smith RV, Waller ES, Doluisio JT, Bauza MT, Puri SK, Ho I, Lassman HB. 1986. Pharmacokinetics of orally administered pentoxifylline in humans. J Pharm Sci. 75:47–52.
   PubMed Web of Science ®Google Scholar
• Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, et al. 2007. Tumor necrosis factor-α mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 115:1398–1407.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Minayian M, Moazen E. 2010. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res. 20: 115–123.
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 95: 627–638.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li J, Cho J, Malik AB. 2014. Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nat Nanotechnol. 9:204–210.
   PubMed Web of Science ®Google Scholar
• Waterborg JH. 2009. The Lowry Method for Protein Quantitation. The Protein Protocols Handbook. New York: Humana Press, pp. 7–10.
   Google Scholar
• Zhai Y, Zhao Y, Lei J, Su Z, Ma G. 2009. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J Biotechnol. 142:259–266.
   PubMed Web of Science ®Google Scholar
• Zhang C, Gu C, Peng F, Liu W, Wan J, Xu H, et al. 2013. Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation. Molecules. 18:13340–13356.
   PubMed Web of Science ®Google Scholar
• Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, Dhalla NS. 2005a. Pentoxifylline attenuates cardiac dysfunction and reduces TNF-∝ level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol. 289:H832–H839.
   PubMed Web of Science ®Google Scholar
• Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, Dhalla NS. 2005b. TNF-α as a potential mediator of cardiac dysfunction due to intracellular Ca2+-overload. Biochem Biophys Res Commun. 327:57–63.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang L, Yan M, Ma Y, Zang G, She Z, Deng Y. 2012. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomed. 7:2891–2900.
   PubMed Web of Science ®Google Scholar
• Zou Y, Ding J, Zheng Z, Zhang L, Ma N. 2012. Preparation and in vitro–in vivo evaluation of long-circulating solid lipid nanoparticles loaded with praziquantel. Chin J Pharm. 43:438–442.
   Google Scholar